Edmond DE Rothschild Holding S.A. decreased its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 138,702 shares of the company’s stock after selling 3,815 shares during the quarter. Edmond DE Rothschild Holding S.A. owned approximately 0.10% of Ionis Pharmaceuticals worth $11,258,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. grew its stake in shares of Ionis Pharmaceuticals by 12.1% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 1,485 shares of the company’s stock worth $121,000 after acquiring an additional 160 shares during the last quarter. Carroll Financial Associates Inc. grew its stake in shares of Ionis Pharmaceuticals by 27.4% in the first quarter. Carroll Financial Associates Inc. now owns 762 shares of the company’s stock worth $61,000 after acquiring an additional 164 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Ionis Pharmaceuticals by 9.0% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,268 shares of the company’s stock worth $184,000 after acquiring an additional 188 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Ionis Pharmaceuticals by 29.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock worth $48,000 after acquiring an additional 200 shares during the last quarter. Finally, Keybank National Association OH grew its stake in shares of Ionis Pharmaceuticals by 1.2% in the fourth quarter. Keybank National Association OH now owns 21,606 shares of the company’s stock worth $1,168,000 after acquiring an additional 250 shares during the last quarter. 82.67% of the stock is currently owned by institutional investors.
Shares of IONS traded down $0.42 on Friday, hitting $64.27. The company’s stock had a trading volume of 1,485,836 shares, compared to its average volume of 1,220,720. The company has a quick ratio of 9.36, a current ratio of 9.40 and a debt-to-equity ratio of 0.47. The business has a fifty day moving average of $65.48. Ionis Pharmaceuticals Inc has a fifty-two week low of $41.05 and a fifty-two week high of $86.58. The stock has a market capitalization of $9.08 billion, a price-to-earnings ratio of 21.71 and a beta of 2.28.
In related news, Chairman Stanley T. Crooke sold 32,000 shares of the stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $84.84, for a total value of $2,714,880.00. Following the sale, the chairman now owns 79,634 shares in the company, valued at approximately $6,756,148.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Patrick R. O’neil sold 7,654 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $84.83, for a total value of $649,288.82. Following the completion of the transaction, the senior vice president now directly owns 27,327 shares in the company, valued at $2,318,149.41. The disclosure for this sale can be found here. In the last quarter, insiders have sold 223,422 shares of company stock worth $17,675,548. Company insiders own 2.40% of the company’s stock.
IONS has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 price target on the stock in a research note on Tuesday, March 26th. TheStreet raised Ionis Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, March 1st. JPMorgan Chase & Co. lifted their price target on Ionis Pharmaceuticals from $47.00 to $55.00 and gave the company a “neutral” rating in a report on Monday, March 18th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Ionis Pharmaceuticals in a report on Thursday, April 18th. Finally, BMO Capital Markets boosted their price objective on Ionis Pharmaceuticals from $70.00 to $82.00 and gave the stock an “outperform” rating in a report on Thursday, February 28th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $68.25.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
See Also: Why are percentage decliners important?
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.